Cancer Drug Clinical Trial Endpoints Should Consider Quality-Of-Life PROs, Advocate Says

 
• By Brenda Sandburg
  
Clinical trial
Patient advocate petitions FDA to amend its guidance on clinical trial endpoints for cancer drugs • Source: Shutterstock

More from Approval Standards

More from Pathways & Standards